Entheon Biomedical Corp. (ENTBF)
| Previous close | 0.0570 |
| Open | 0.0440 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0440 - 0.0713 |
| 52-week range | 0.0280 - 0.5710 |
| Volume | |
| Avg. volume | 18,558 |
| Market cap | 4.176M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1060 |
| Earnings date | 28 Oct 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research
AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision med
- GlobeNewswire
Microdose Psychedelic Insights Presents the Upcoming DMT Conference, a Deep Dive Into the Dynamic Field of DMT Therapeutics
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting the upcoming DMT Conference in an entirely virtual format Sept. 9-10, 2021. The virtual event will explore the potential of DMT (“Dimethyltryptamine”) at the intersection of drug development and safety,
